As China accounts for roughly 40% of the global active pharmaceutical ingredients production, the outbreak of the novel coronavirus could potentially disrupt the drug supply and business of branded and generic drug manufacturers. Since the emergence of COVID-19, drug...
The Coronavirus Ripple Effect: Analyzing the Challenges Impacting New Drug Development
read more